Exploring Hemp-Derived CBD to Help People with Cannabis Use Disorder
Hemp-derived Cannabidiol for the treatment of cannabis use disorder in concentrate users: A double-blind placebo-controlled randomized trial
['FUNDING_R01'] · UNIVERSITY OF COLORADO · NIH-11128533
This project looks at whether widely available hemp-derived CBD can help adults who use high-potency cannabis concentrates reduce their cannabis use and manage withdrawal symptoms.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF COLORADO (nih funded) |
| Locations | 1 site (Boulder, UNITED STATES) |
| Trial ID | NIH-11128533 on ClinicalTrials.gov |
What this research studies
As cannabis products with very high THC levels become more common, we are seeing more people struggle with cannabis use disorder (CUD) and experience more severe withdrawal. Previous research suggests that cannabidiol (CBD), a non-intoxicating compound from cannabis, might help reduce cannabis use and related symptoms like anxiety and withdrawal. However, those studies used special forms of CBD that are not easily available. This project will test two types of hemp-derived CBD, one with a tiny bit of THC and one without, to see if they can help people reduce their use of high-potency cannabis concentrates compared to a placebo.
Who could benefit from this research
Good fit: Ideal candidates are adults aged 21 or older who regularly use high-potency cannabis concentrates and experience symptoms of cannabis use disorder.
Not a fit: Patients who do not use cannabis concentrates or do not have cannabis use disorder would likely not benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this could offer a new, accessible, and non-prescription treatment option for individuals struggling with cannabis use disorder, especially those who use high-potency concentrates.
How similar studies have performed: Previous studies using synthetic or isolated CBD have shown promising results in reducing cannabis use and related symptoms, but this is the first to test widely available hemp-derived CBD.
Where this research is happening
Boulder, UNITED STATES
- UNIVERSITY OF COLORADO — Boulder, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BIDWELL, L. CINNAMON — UNIVERSITY OF COLORADO
- Study coordinator: BIDWELL, L. CINNAMON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.